- Sanofi is investing €200 million in Höchst next year.
- A fully automated cold warehouse for insulin and antibodies will be built.
- A new multi-purpose building with labs and offices will be constructed.
- 500 jobs have been created with the launch of Toujeo.
Investment and Expansion
Sanofi is planning to invest €200 million in the Höchst Industrial Park in Frankfurt next year. This follows an investment of €160 million this year and an average of €100 million annually in recent years. The expansion includes the construction of two new buildings, aimed at enhancing the company's capabilities in research, development, and manufacturing.
New Facilities
One of the new buildings will be a fully automated cold warehouse for insulin and antibodies, allowing Sanofi to bring previously outsourced logistics services in-house. The second building will be a multi-purpose facility with laboratories and offices, located near the existing insulin-pen manufacturing plant, which will also be expanded due to high demand.
Focus on Diabetes Treatment
Sanofi's commitment to diabetes treatment is a significant part of its operations in Frankfurt. The new facilities will support research and development in insulin production and the manufacture of insulin-pens. This expansion is expected to strengthen the company's position in the market and improve its production capabilities.
Job Creation
The expansion has already led to the creation of 500 new jobs, linked to the launch of the long-acting human insulin Toujeo. Since its introduction in May 2015, Toujeo has achieved a significant market share in Germany, contributing to Sanofi's growth in the diabetes treatment sector.
